The $50 billion molecule reshaping medicine
GLP1Bio.com is the premium domain for GLP-1 receptor agonist therapeutics - the class of drugs behind Ozempic, Wegovy, and Mounjaro that's transforming obesity, diabetes, and cardiometabolic medicine.
The biggest drug class launch in history.
GLP-1 agonists aren't just weight loss drugs - they're showing efficacy across cardiovascular disease, NASH, addiction, and neurodegeneration.
Obesity
15-20% weight loss sustained. Wegovy and Zepbound are transforming how medicine treats the obesity epidemic.
Cardiovascular
20% reduction in major cardiac events. GLP-1s are becoming standard of care for cardiometabolic disease.
Pipeline
Oral formulations, combination therapies, next-gen molecules. Every major pharma company is racing in this space.
Growth
From $2B in 2020 to $50B+ projected by 2030. The fastest-growing drug class in pharmaceutical history.
Own the molecule.
GLP1Bio.com is the definitive domain for GLP-1 biology, therapeutics, and the incretin revolution.
Ideal for biotech startups, pharmaceutical companies, clinical research organizations, or health platforms focused on metabolic medicine.